

# OPTIMA HEALTH COMMUNITY CARE

## (MEDICAID)

### PHARMACY PRIOR AUTHORIZATION/STEP-EDIT REQUEST\*

**Directions:** The prescribing physician must sign and clearly print name (preprinted stamps not valid) on this request. All other information may be filled in by office staff; **fax to 1-844-348-3720**. No additional phone calls will be necessary if all information (including phone and fax #s) on this form is correct. **Incomplete form will delay authorization process.**

**Drug Requested:** Nucala™ SQ (mepolizumab) (J2182) (Medical)  
{Severe Eosinophilic Asthma (SEA)}

**DRUG INFORMATION:** Complete information below to ensure authorization will **NOT** be delayed.

**Drug Form/Strength:** \_\_\_\_\_

**Dosing Schedule:** \_\_\_\_\_

**Length of Therapy:** \_\_\_\_\_

**Diagnosis:** \_\_\_\_\_

**ICD Code:** \_\_\_\_\_

**RECOMMENDED DOSAGE:** 100 mg SubQ every 4 weeks

**CLINICAL CRITERIA:** Check **ALL** applicable boxes below to qualify. **All** Chart notes, including lab values, **MUST** be submitted with form. If **not** checked or included, authorization could be delayed.

A diagnosis of severe eosinophilic asthma and the following criteria must be met:

A blood eosinophil count of at least 150 cells/microliter at the initiation of treatment

**OR**

A blood eosinophil count of at least 300 cells/microliter in the past 12 months

**AND**

The patient is being followed by an allergist, immunologist, or pulmonologist

**AND**

Clinical documentation that the patient is compliant with high-dose inhaled corticosteroids (ICS) and long-acting inhaled beta-2 agonists (LABA) for at least 90 days consecutively within the year of request and use of oral corticosteroids for exacerbation

**AND**

Member must submit eosinophil blood count after a trial and failure of at least 90 days consecutively with high dose inhaled corticosteroids and long-acting inhaled beta-2 agonist. A failure of these medications is defined as a blood count > 150 cells/microliters (**within 8 months**)

**AND**

(continued on next page)

- Has experienced  $\geq 2$  exacerbations in the previous 12 months requiring additional medical treatment (oral corticosteroids, emergency department or urgent care visits, or hospitalizations)

**Medication being provided by a Specialty Pharmacy - PropriumRx**

***\*\*Use of samples to initiate therapy does not meet step-edit/preauthorization criteria.\*\****

***\*Previous therapies will be verified through pharmacy paid claims or submitted chart notes.\****

Patient Name: \_\_\_\_\_

Member Optima #: \_\_\_\_\_ Date of Birth: \_\_\_\_\_

Prescriber Name: \_\_\_\_\_

Prescriber Signature: \_\_\_\_\_ Date: \_\_\_\_\_

Contact Office Name: \_\_\_\_\_

Phone Number: \_\_\_\_\_ Fax Number: \_\_\_\_\_

DEA OR NPI #: \_\_\_\_\_

**\*REVISED/UPDATED:** 8/1/2017; 6/19/18; 7/13/2018; 8/27/2018; 10/8/2018 (Reformatted) 2/5/2019;